The largest database of trusted experimental protocols

108 protocols using clone mib 1

1

Assessing Metabolic Treatments on Cell Proliferation in ccRCC and Normal Cortex

Check if the same lab product or an alternative is used in the 5 most similar protocols
To assess the effect of metabolic treatments on cell proliferation of ccRCC and normal cortex primary cultures 1 × 105 cells seeded onto coverslips were treated with 2DG or Etomoxir for 72 hours. Immunofluorescence staining was performed using mouse monoclonal antibody against Ki67 (1:75 dilution; Clone MIB-1; DAKO, Glostrup, Denmark) and Alexa Fluor 488 goat anti-mouse polyclonal secondary antibody (1:100 dilution; Molecular Probes, Carlsberg, CA) as previously described [15 (link)]. Nuclei were counterstained with DAPI. For each treatment, Ki67 positive nuclei were quantified in at least five immunofluorescence micrographs, obtained at 400x magnification using a Zeiss LSM710 confocal microscope and Zen2009 software (Zeiss, Oberkochen, Germany), and normalized by total nuclei. Normalized Ki67 positive cells in treated samples were expressed as percentage of corresponding untreated samples.
+ Open protocol
+ Expand
2

Clinicopathological Characterization of Participants

Check if the same lab product or an alternative is used in the 5 most similar protocols
Participants were characterized clinically including sex, age, and body mass index (BMI). The latter was subdivided into the four categories defined by World Health Organization (WHO): underweight (<18.5 kg/m2), normal weight (≥ 18.5 to < 25.0 kg/m2), overweight (≥ 25.0 to < 30.0 kg/m2), obesity (>30.0 kg/m2).
Participants were characterized pathologically including histology, tumor stage, tumor grading, Ki-67 staining (clone MiB-1; monoclonal mouse from Dako, dilution 1:100).
Tumor tissue was characterized histopathologically and tumor stage was established according to the 4th edition of World Health Organization classification [10] (link), the 8th edition of TNM classification of malignant tumors [11] (link), respectively.
+ Open protocol
+ Expand
3

Immunohistochemical Analysis of Ki67 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sectioned tumour slides were deparaffinized and rehydrated. The sections were
incubated in antigen retrieval (pH 9.0), washed with TBST washing buffer and
incubated with Dako® peroxidase blocking reagent for 1 h. The
sections were then washed with TBST (three times, 5 min per wash). The slides
were blocked using blocking solution (10% goat serum and 5% BSA in TBST) for
1 h. Slides were then washed again and incubated with primary antibodies against
Ki67 (Dako, Clone MIB-1, Cat#M7240, mouse monoclonal) overnight at 4°C.
Subsequently, the slides were washed and incubated with biotinylated secondary
antibody for 1 h, followed by washing with TBST (three times, 5 min each) to
remove unbounded antibodies. The sections were incubated with ABC solution for
1 h, and remaining solutions were removed through washing with TBST as
previously described. Finally, 200 µl of Dako® DAB solution was
applied to each section, and samples were monitored closely to examine the
development of stains. The slides were counterstained with haematoxylin, washed,
left to dry overnight and mounted. Slides were imaged using a light microscope
(CX41, Olympus) at 100× magnification. The ratio of stained cells
versus total cells were scored using Image J software.
+ Open protocol
+ Expand
4

Standardized Ki-67 Immunohistochemistry Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ki-67 scores were retrospectively obtained from pathology reports at initial diagnosis on the primary tumor prior to any treatment. IHC staining on formalin-fixed paraffin-embedded tissue sections was performed. Mind Bomb 1 mouse monoclonal antibody (manufactured by Dako) was used to detect Ki-67. The staining protocol included de-paraffinization (30 minutes at 72°C) and rehydration with antigen retrieval performed at 100°C for 20 minutes with Tris-EDTA buffer, pH 6.0. Endogenous peroxidase was blocked with 3% peroxide for 5 minutes. Primary anti-Ki-67 antibody (Dako, clone MIB-1) was applied at 1:100 dilution for 15 minutes. Post primary antibody detection was carried out using a commercial polymer system (Bond Polymer Refine Detection, Leica), and stain development was achieved by incubation with diaminobenzidine (DAB) and DAB enhancer (Leica). The robust quality control and quality improvement program of the IHC lab at MDA was fully applied to the anti-Ki-67 IHC assay. A positive control was added to every IHC run (reference tonsil tissue, batch control) and was reviewed by a member of the IHC medical directorship team. Records of batch control results were documented daily in internal laboratory records. Stains were evaluated by designated breast pathologists, who visually estimated the percentage of positively staining invasive carcinoma cells.
+ Open protocol
+ Expand
5

Histological and Immunohistochemical Tumor Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
All tissue samples were histologically classified according to the WHO classification of tumors of the central nervous system.[19 (link)] Additional immunohistochemistry (IHC) study was performed with antibodies against proliferation-associated antigen Ki-67 (clone: MIB-1, primary antibody dilution: 1:200; Dako) following standard protocols. IHC results of the Ki-67 index were quantified using semiquantitative staining scores according to cell and vascular density.[20 (link),21 (link)]
+ Open protocol
+ Expand
6

Immunohistochemical Analysis of Ki-67 and 5-mc

Check if the same lab product or an alternative is used in the 5 most similar protocols
Haematoxylin and eosin staining were performed as previously described (Maharani et al., 2018 (link)). Immunohistochemistry analysis was performed as previously described (Gulay et al., 2021 (link)) with slight modifications, as described below. Heat‐induced antigen retrieval was performed twice in Tris‐EDTA buffer (pH 9.0) in a microwave oven for 5 min. Tissues were stained with mouse anti‐Ki‐67 monoclonal antibody (Clone MIB‐1, DAKO) and mouse anti‐5mc monoclonal antibody (33D3, Abcam) overnight at 4°C. To measure the Ki‐67 labelling index, more than 1000 cells were counted in randomly selected high‐power fields, and the number of Ki‐67‐positive nuclei was recorded in each field. The labelling index was defined as the ratio of Ki‐67‐labelled cells to the total number of cells counted and was expressed as a percentage. 5mc values were calculated from OD mean value from >1000 cells in each patient analysed by QuPath ver. 0.2.1 (Bankhead et al., 2017 (link)).
+ Open protocol
+ Expand
7

Breast Cancer Biomarker Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Samples were centrally stained for ER, PR (ER/PR pharmDx™ Kit, Dako), HER2 (HercepTest™ Kit, Dako) and Ki67 (clone MIB-1, dilution 1:100, DAKO). ER and PR were scored according to the Allred scoring system and considered positive when the Allred score was 3 or above. HER2 positivity was defined as 3+ if more than 10% of cells displayed a strong complete membrane staining, according to the ASCO-CAP guidelines 2013.
All samples were stained for AP2γ (TFAP2C) by immunohistochemistry. Briefly, antigen retrieval was performed by heating in Target Retrieval Solution Citrate pH 6.0 (DAKO) using a pressure cooker for 10 min. Slides were incubated with the AP2γ primary antibody (clone 6E4/4, SantaCruz) at a dilution of 1:300 for 30 min at room temperature. The DAKO REAL™ Detection System Peroxidase/DAB+ was used with an automated protocol. Tumors were scored according to the Allred score (0–8). Tumors with scores 0–2 were defined as AP-2γ negative, while tumors with scores 3–8 were defined as AP-2γ positive. Whenever present, myo-epithelial cells served as positive internal control.
+ Open protocol
+ Expand
8

Immunohistochemical Analysis of Ki67 LI

Check if the same lab product or an alternative is used in the 5 most similar protocols
After tumor resection, histopathologic and immunohistochemical analysis was performed. In this analysis, Ki67 LI was measured. Tissues were obtained from formalin-fixed (4%), paraffin-embedded blocks cut into 3-5 µm sections. All sections were mounted on poly-L-lysine coated slides and left in a 45 °C incubator overnight before staining. The slides were deparaffinized in xylene and rehydrated with a series of decreasing ethanol concentrations and finally distilled water. Antigen retrieval was performed immersing the slides in a thermostat bath with preheated 10 mmol/L citrate buffer (pH 6.0) for 40 minutes at 97 °C, and after that cooled at room temperature for 20 minutes. Then the slides were treated with 3.0% H2O2 in distilled water for 10 minutes, to block endogenous peroxidase activity. After blocking nonspecific antigen with normal rabbit serum for 10 minutes, the slides were incubated for 30 minutes at room temperature with anti-human Ki-67 antibody (1:200; Clone MIB-1, Code M7240; Dako, Glostrup, Denmark). Negative controls were obtained by omitting the primary antibody. Only definite nuclear staining was regarded as positive. Cases were scored by the percentage of tumor cells that stained, determined in more visual fields with the most intense staining (hot spot).
+ Open protocol
+ Expand
9

Breast Cancer Immunohistochemistry Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
All cases were reviewed by two breast pathologists (DH and LY) to assess tumor grade (using the Nottingham histological three-tier grading system), tumor size, nodal status, ER, PgR, HER2, and Ki67 expression. The expression of ERα (clone EP1; Dako, Glostrup, Denmark, prediluted), PgR (clone PgR1294; Dako, prediluted), and Ki67 (clone MIB1; Dako, prediluted) were determined by immunohistochemistry (IHC) during routine pathologic examination. ER and PgR status was determined based on the percentage of positive nuclei in the invasive neoplastic compartment of the tissue. Tumors were classified as ER- or PgR-positive when ≥1% invasive tumor cells showed definite nuclear staining, regardless of staining intensity. Ki67 was evaluated as the percentage of positively stained nuclear cancer cells (regardless of staining intensity). HER2 expression was evaluated with the HercepTest kit (Dako) and scored as 0, 1+, 2+, or 3+, according to the ASCO-CAP guidelines. Tumors scored as 2+ were re-tested with FISH using the HER2 IQFISH PharmDx kit (Dako).
+ Open protocol
+ Expand
10

Immunohistochemistry Profiling of Tissue Microarrays

Check if the same lab product or an alternative is used in the 5 most similar protocols
TMA blocks were cut into 4-µm sections. IHC reactions were performed using the Dako Autostainer Link48 (Dako, Glostrup, Denmark). Deparaffinisation, rehydration, and epitope retrieval (97°C, 20 min) were performed using a low pH Target Retrieval Solution (Dako/Agilent Technologies, Santa Clara, CA, USA) in a PT- Link (Dako). Subsequently, the sections were washed in Tris-buffered saline and incubated with primary antibodies at room temperature for 20 min. The following specific primary antibodies were used: polyclonal rabbit anti-Periostin (dilution 1:200; code no.NBP1-82472; Novus Biologicals, Littleton, CO, USA), monoclonal mouse anti-Ki-67 antibody (ready-to-use, Clone MIB-1, code IS626; Dako), anti-TTF-1 (ready-to-use, Clone 8G7G3/1, code IR056; Dako), anti-p63 (ready-to-use, Clone DAK-p63, code IR662; Dako), anti-Podoplanin (ready-to-use, clone D2-40 (PDPN), code ISO072; Dako), anti-Vimentin (ready-to-use, clone V9, code GA630; Dako), and anti-αSMA (ready-to-use, clone IS611, code 1A4; Dako). The sections were then visualized using an EnVision FLEX kit (Dako). All slides were counterstained with haematoxylin (Dako). Negative control sections were generated in the absence of the primary antibody.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!